Sign in

NCT06022016Recruiting

Study of Families With an Hemopathies Predisposition Related to the DDX41 Gene.

Source: ClinicalTrials.gov · Last updated 8 Dec 2025

Brief summary (registry, in English)

This is a multicenter, interventional, historico-prospective cohort pilot study aimed at specifying the phenotype of subjects carrying a constitutional familial DDX41 mutation, with a view to eventually publishing oncogenetic recommendations for carriers of this mutation. The main objective of the LUCID project is to assess the cumulative risk of hematological diseases as a function of age in DDX41 germline mutation carriers. This study will be carried out in two stages: Stage 1: Inclusion of index cases in an oncogenetic consultation (salivary test, completion of an health self-questionnaire and collection of contact details for the related cases). Stage 2: Proposition of participation to family members, by correspondence, and determination of carrier or non-carrier status of the constitutional familial DDX41 mutation (based on a salivary test). A maximum of 210 index case patients and 700 family member will be included in this study.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
910 (estimated)
First submitted
28 Aug 2023
Start date
17 Nov 2023
Primary completion date
31 Jan 2030
Lead sponsor
Institut Claudius Regaud
NCT number
NCT06022016

What you commit to

  • Study type: Interventional
  • Planned participants: 910
  • From 17 Nov 2023 to the primary completion date, 31 Jan 2030
  • 5 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • No history of hemopathy or no current hemopathy.

Other

  • Patient (or beneficiary) unable to complete questionnaire for social or psychological reasons.
  • Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).
    • Related cases (Family member):
  • Not applicable from version 2 of the protocol. Related in the 4th or 5th degree to an index case included in the LUCID study.
  • Person already identified as an index case in the LUCID study.
  • Person unable to complete questionnaire for social or psychological reasons.
  • Person who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).

Who the study is looking for

  • Women or man aged ≥ 18 years old.
  • Personal history(s) of hemopathy or patient with hemopathy at the time of inclusion.
  • Patient with a tumor mutation of DDX41 with an allelic frequency (AF) ≥ 30% (with total depth of nucleotide position \>300x: provide tumor molecular analysis report).
    • Special case of inclusion of deceased index cases: the DDX41 tumor mutation of interest must be accompanied by another somatic DDX41 mutation (the most frequent being p.R525H).
    • Or patient known to be a constitutional carrier of a DDX41 mutation confirmed after oncogenetic consultation (in this case, provide constitutional analysis report).
  • Patient (or beneficiary) agreeing to release results of oncogenetic report.
  • Patient (or beneficiary) agrees to communicate the contact details of his relatives and that they may be contacted by mail to participate in the LUCID study.
  • Patient affiliated to a Social Health Insurance in France.
  • Patient able to participate and willing to give informed consent prior performance of any study-related procedures.
  • Women or man aged ≥ 18 years old.
  • Related to an index case included in the LUCID study.
  • Agreeing to carry out a scientific salivary test for the constitutional research of the DDX41 mutation.
  • Patient affiliated to a Social Health Insurance in France.
  • Patient able to participate and willing to give informed consent prior performance of any study-related procedures.

Criteria the registry did not label

  • Index cases:

Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (5)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
CHU de Bordeaux
Coordinator of this site? Confirm its status
BordeauxFranceRecruiting
CHU de Limoges
Coordinator of this site? Confirm its status
LimogesFranceRecruiting
Institut Paoli-Calmettes
Coordinator of this site? Confirm its status
MarseilleFranceRecruiting
CHU de Montpellier
Coordinator of this site? Confirm its status
MontpellierFranceRecruiting
IUCT-O
Coordinator of this site? Confirm its status
ToulouseFranceRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.